In vivo, when administered to mice with established orthotopic pancreatic tumors, sangivamycin led to a significant decrease in tumor burden, correlating with a collapse of tumor vasculature, decrease in Ki67 positive cells and an increase in cleaved-caspase 3 expression (Fig. 5 and Supplemental Fig. S3). Here, CASP3 is linked to neoplasm.